SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's earnings have sparked intense debate, with a revenue beat overshadowed by an EPS miss, triggering volatility. The community is focused on the upcoming conference call with Elon Musk, anticipating insights on robotaxis and AI. Broader discussions revolve around Tesla's valuation and future growth prospects in the evolving EV market.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending amidst anticipation for upcoming earnings, with the community eager for updates on partnerships and production milestones. Discussions revolve around the potential impact of earnings on the stock's price, as well as speculation regarding a possible partnership with Panasonic and the unveiling of a second OEM. Despite some concerns about market conditions and short selling, many investors express long-term confidence in the company's technology and future prospects in the battery sector.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its community rallies around the idea of 'OG memes' making a comeback, emphasizing community building and a rejection of traditional 'coining'. The community is expressing strong conviction, with many calling for moonshot listings and celebrating its current trending status. Talk centers around the idea that while markets may be uncertain, the 'rage' will continue.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending as investors discuss the recent earnings call, pipeline progress, and cash runway, with some expressing concerns about cash burn while others highlight the potential for partnerships and buyout opportunities. The community is weighing the company's prospects in the competitive GLP-1 market against its financial health and the CEO's strategy. Discussions also involve technical analysis, short positions, and potential catalysts for stock movement.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending due to a recent breakthrough in quantum computing with HSBC, demonstrating improved bond trading predictions, which has sparked excitement about the company's leadership in the sector. The community is discussing IBM's growing AI and quantum capabilities and the potential impact on its stock value. Broader market context includes IBM's strategic shift towards AI and cloud computing.

Molina Healthcare, Inc. engages in the provision of health care services. It operates through the following segments: Medicaid, Medicare, Marketplace, and Other. The company was founded by C. David Molina in 1980 and is headquartered in Long Beach, CA.

Molina Healthcare Inc

MOH is trending due to a significant earnings miss, sparking concerns about rising medical costs and the impact of Medicaid trends across the healthcare sector. Community members are discussing potential support levels and comparing MOH to competitors like CNC and UNH, while also speculating on potential catalysts like ACA subsidy extensions. The broader context involves uncertainty around government healthcare policy and its effect on managed care organizations.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is trending amid discussions about earnings, with some celebrating a significant beat while others express concerns about tariffs and broader market conditions. The community is focused on whether the stock's upward momentum can be sustained. Bullish sentiment seems to be building around the company's potential in AI and memory markets.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

Armata Pharmaceuticals Inc

Armata Pharmaceuticals is trending due to positive Phase 2a trial results for its AP-SA02 drug, showing promise in treating Staphylococcus aureus bacteremia; the community is excited about the potential for advancement into Phase 3 and the drug's efficacy against antibiotic-resistant strains. Some traders are pointing to the low float and a partnership with Gilead as reasons to be bullish, while others caution about potential dilution and the company's cash runway.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending as investors discuss the implications of recent study results for its cystic fibrosis treatment, with community analysis focusing on the potential for higher doses to yield better outcomes. Despite some disappointment in initial lung function improvements, there's optimism around mucus reduction data and potential future catalysts like CSL royalties and lawsuit updates. The community speculates on potential buyouts and the company's overall pipeline value.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene Corp. is trending as investors react to sector-wide pressures, particularly following Molina's earnings miss, which has sparked concerns about Medicaid margins and dragged down other healthcare stocks. The community is actively debating whether the dip represents a buying opportunity ahead of Centene's upcoming earnings, with some highlighting its undervalued status and potential for a V-shaped recovery contingent upon ACA subsidy extensions and positive earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR...

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in...

Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $33.54, denoting a -3.44% move from the preceding trading day.

Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?

VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.

The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics

Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.

NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio

Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.

How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?

Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025 Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025 PR Newswire SAN...

Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note

Viking Therapeutics, Inc. (VKTX) closed at $33.05 in the latest trading session, marking a -2.54% move from the prior day.

Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?

NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.

https://files.quartr.com/streams/2025-10-22/6a020f4a-5c3b-498f-9005-342e3161e153/2/live_transcript.jsonl?ref=U3RvY2t0d2l0cw==

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.70	--	--	N/A
Q2 '25	-$0.45	-$0.58	-29.90%	MISSED
Q1 '25	-$0.33	-$0.41	-25.00%	MISSED
Q4 '24	-$0.27	-$0.32	-17.65%	MISSED
Q3 '24	-$0.24	-$0.22	9.42%	BEAT

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest VKTX News

VKTXViking Therapeutics Inc